| Ytd | -41.69% | |
| 1y | -67.04% |
| Open | 12.17 | Prev Close | 12.28 | Low | 11.95 | High | 12.19 | Mkt Cap | 1.99B |
| Vol | 352.29K | Avg Vol | 1.64M | EPS | 0.66 | P/E | 18.61 | Forward P/E | 14.88 |
| Beta | 0.83 | Short Ratio | 4.58 | Inst. Own | 102.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 12.64 | 200-d Avg | 16.31 | 1yr Est | 18.00 |
VERX News
Morgan Stanley analyst Chris Quintero downgrades Vertex (NASDAQ:VERX) from Overweight to Equal-We
Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual
KING OF PRUSSIA, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provid
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of V
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billi
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crine
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated i
On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Man
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceutical
Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late
Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The dea
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second q
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acqui
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceutic
The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion
Crinetics stock nearly doubled late Monday after Vertex Pharmaceuticals pledged $10 billion to buy t
Vertex Pharmaceuticals will buy Crinetics Pharmaceuticals for a total equity value of about
BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetic
Vertex's business is growing modestly but there's much more growth potentially on the horizon. The s
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the
TD Cowen analyst Jared Levine initiates coverage on Vertex (NASDAQ:VERX) with a Buy rating and an
On Wednesday, 807 companies reached new 52-week lows.
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report
Friday's session saw 466 companies set new 52-week highs.